Statins: Mechanism of action and effects

Journal of Cellular and Molecular Medicine

Volumn 5, Issue 4, 2001, Pages 378-387

  Stancu, Camélia ^a   Sima, Anca ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Atherosclerosis; Cancer osteoporosis; Cell signaling; Endothelial dysfunction; Hmg coa reductase; Ldl oxidation; Macrophage; Smooth muscle cell

Indexed keywords

CHOLESTEROL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CLASSIFICATION; CYTOLOGY; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIVER; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

CHOLESTEROL ESTERS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIVER; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; PLATELET ACTIVATION; SIGNAL TRANSDUCTION;

EID: 0035528772     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2001.tb00172.x     Document Type: Article

References (41)

1. Vaughan C.J., Gotto A.M., Basson C.T., The evolving role of statins in the management of atherosclerosis, J. Am. Coll. Cardiol., 35: 1-10,2000
2. Hunninghake D.B., HMG-CoA reductase inhibitors, Curr. Opin. Lipidoi, 3: 22-8, 1992
3. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A., Non-lipid-related effects of statins, Ann. Med.,32: 164-176,2000
4. Meier C.R., Schlienger R.G, Kraenzlin M.E., Schlegel B., Jick H., HMG-CoA reductase inhibitors and the risk of fractures, JAMA, 283: 3205-3210,2000
5. Blum C.B., Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Am. J. Cardiol., 73: 3D-11D, 1994
6. Lennernas H., Fager G, Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences, Clin. Pharmacokinet., 32: 403-425, 1997
7. Blumenthal RS., Statins: Effective antiatherosclerotic therapy, Am. Heart. J., 139: 57783,2000
8. Corsini A., Bellosta S., Baetta R., Fumagalli R., Bernini F., New insights into the pharmacodynamics and pharmacokinetic properties of statins, Pharmacol. Ther., 84: 413-28, 1999;
9. Sehayek E., Butbul E., Avner R., Enhanced cellular metabolism of very low density lipoprotein by simvastatin: a novel mechanism of action of HMG-CoA reductase inhibitors, Eur. J. Clin. Invest., 24: 173-8, 1994
10. Stein E.A., Lane M., Laskarzewski P., Comparison of statins in hypertriglyceridemia, Am. J. Cordial., 81: 66B-69B, 1998
11. Ginsberg H.N., Le N.A., Short M.P., Ramakrishnan R., Desnick R.J., Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implication for regulation of apolipoprotein B synthesis,/ Clin. Invest.,80: 1692-1697, 1987
12. Gaw A., Packard C.J., Murray E.E, Effects of simvastatin on apoB metabolism and LDL subfraction distribution, Arterioscler. Thromb., 13: 170-89, 1993
13. Marais A.D., Naumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R., Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia, J. Lipid Res., 38: 2071-2078, 1997
14. Raal FJ., Pilcher G.J., Illingworth D.R., Pappu A.S., Stein E.A., Laskarzewski P., Mitchel Y.B., Melino M.R., Expanded dose simvastatin is effective in homozygous familial hypercholesterolemia, Atherosclerosis, 135: 249256, 1997
15. Kostner G.M., G a vis h D., Leopold B., Bolzano K., Weintraub M.S., Breslow J.L., HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels, Circulation, 80: 1313-1319, 1989
16. Aviram M., Hussein O., Rosenblat M., Schlezinger S., Hayek T., Keidar S., Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy, J. Cardiovasc. Pharinacol, 31: 39-45, 1998
17. Hoffman R., Brook GJ., Aviram M., Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies, Atherosclerosis, 93: 105-13, 1992
18. Wagner A.H., Kohler T., Ruckschloss U., Just L, Hecker M., Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial Superoxide anion formation, Arterioscler. Thromb. Vase. Biol., 20: 619,2000
19. Chen L., Haught W.H., Yang B., Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine, J. Am. Coll. Cardiol., 30: 569-75, 1997
20. Hrboticky N., Draude G., Hapfelmeier G, Lorenz R., Weber P.C., Lovastatin decreases the receptormediated degradation of acetylated and oxidized LDLs in human blood monocytes during early stage of differentiation into macrophages, Arterioscler. Tlirom. Vase. Biol., 19: 1267-75, 1999
21. Pietsch A., Erl W., Lorenz R.L., Lovastatin reduces the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells, Biochem. Pharmacoi, 52: 433, 1996
22. Voet D., Voet J.G, Lipids and membranes. In: John Wiley & Sons, Inc., eds., Biochemistry, Second Edition, USA, 1995, pp. 315-316
23. Bernini F., Didoni G, Bonfadini G, Bellosta S., Fumagalli R., Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages, Atherosclerosis, 104: 19-26, 1993
24. Bernini F., Scurati N., Bonfadini G, Fumagalli R., HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages, Arterioscler. Thromb. Vase. Biol., 15: 1352-8, 1995
25. Laufs U., Fata V.L., Plutzky J., Liao J.K., Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors, Circulation, 97: 1129-1135, 1998
26. Simionescu M., Stancu C., Costache G., Sima A., Endothelial cell response to hyperlipemia: activation- dysfunction- injury; the protective role of simvastatin, Gen. Pharin., 2001 (in press)
27. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, 95: 8880-8885, 1998
28. Ross R., Atherosclerosis - an inflammatory disease, N. Engl. J. Med. 340:115-26, 1999
29. Weber C., Erl W., Weber K.S.C., Weber P.C., HMG-CoA reductase inhibitors decrease CDllb expression and CD lib-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia, J. Am. Coll. Cardiol., 30: 1212-7, 1997
30. Bustos C., Hernandez-Presa H., Ortego M., Tunon J., Ortega L., Perez F., HMG-CoA reductase inhibition by atorvastatin reduces neointimal
31. inflammation in a rabbit model of atherosclerosis, J. Am. Coll. Cardiol, 32: 2057-64, 1998
32. Kimura M., Kurose I., Russell J., Granger D.N., Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats, Arterioscler. Thromb. Vase. Biol., 17: 1521-6, 1997
33. Baetta R., Donetti E., Comparato C., Galore M., Rossi A., Teruzzi C., In vitro and in vivo apoptosis by atorvastatin in stimulated smooth muscle cells, Pharmacol. Res.,36: 115-21, 1997
34. Falk E., Shah P.K., Fuster V., Coronary plaque disruption, Circulation 92: 657-71, 1995
35. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler. Thromb. Vase. Biol, 18: 1671-8, 1998
36. Ballantyne C.M., Herd J.A,. Dünn J.K., Jones P.H., Farmer J.A., Gotto A.M.J., Effects of lipid lowering therapy on progression of coronary and carotid artery disease, Citrr. Opin. Lipidoi, 8: 354361, 1997
37. Stancu C., Niculescu L., Toporan D., Sima A., loan A., Simionescu M., Statins produce antiatherosclerotic effects in coronary heart disease patients, Proceedings of the Romanian Academy, 2001 (in press)
38. Nofer J-R., Tepel M., Kehrel B., Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets: a novel mechanism enhancing platelet activity in hypercolesterolemia, Circulation, 95: 1370-7, 1997
39. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells, Cire. Res., 83: 683-90, 1998
40. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E., Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherosclerosis, Arterioscler. Thromb. Vase. Biol., 17: 265-72, 1997
41. Maron D.J., Fazio S., Linton M.F., Current perspectives on statins, Circulation, 101: 207-213, 2000